Phase II Cisplatin + Temozolomide in Malignant Glial Tumours in Children and Adolescents

• Status: Completed
• Trial end date: 2007-12-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this study is to determine whether the combination of Temozolomide and Cisplatinum is effective in the treatment of malignant glial tumours of children and adolescents

• Phase: Phase 2
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris
• Treatments: Cisplatin; Dacarbazine; Temozolomide

Criteria

Inclusion Criteria:

• Age from 4th birthday and younger than 21st birthday

• Histologically documented malignant glial tumour (WHO classification grade III and IV) : astrocytoma, oligodendroglioma, oligoastrocytoma and mixed tumours

• Measurable and evaluable disease by the imaging criteria (MRI)

• Patient not previously treated by either of the two drugs

Exclusion Criteria:

• Malignant brain stem tumours are excluded